Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9084)
All Articles published online
|
Publishing Process of This Article
|
Jan 14, 2016 (publication date) through Feb 18, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kubo A, Hashimoto H, Takahashi N, Yamada Y. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. World J Gastroenterol 2016; 22(2): 887-894 [PMID: 26811634 DOI: 10.3748/wjg.v22.i2.887] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i2/887.htm |
| Number | Citing Articles |
| 1 |
Giovanni Damiani, Ausilia Manganoni, Simone Cazzaniga, Luigi Naldi. Survey of cutaneous adverse reactions to targeted cancer therapies: value of dermatological advice. Giornale Italiano di Dermatologia e Venereologia 2020; 155(5) doi: 10.23736/S0392-0488.18.06033-9
|
| 2 |
W. W. B. de Kort, S. Spelier, L. A. Devriese, R. J. J. van Es, S. M. Willems. Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review. Molecular Diagnosis & Therapy 2021; 25(2): 123 doi: 10.1007/s40291-021-00518-6
|
| 3 |
Yusuf Acikgoz, Oznur Bal, Gokhan Ucar, Ayse Durnali, Yakup Ergun, Merve Dirikoc, Selin Akturk Esen, Mutlu Dogan. Is there any clinical or laboratory predictive factor for cetuximab-induced skin toxicity?. Expert Opinion on Drug Safety 2021; 20(5): 611 doi: 10.1080/14740338.2021.1893304
|
| 4 |
Yoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara. Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatment. Supportive Care in Cancer 2024; 32(1) doi: 10.1007/s00520-023-08195-3
|
| 5 |
C. Dessinioti, C. Antoniou, A.J. Stratigos. From basal cell carcinoma morphogenesis to the alopecia induced by hedgehog inhibitors: connecting the dots. British Journal of Dermatology 2017; 177(6): 1485 doi: 10.1111/bjd.15738
|
| 6 |
Yoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara. Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody–induced skin toxicities in real-world metastatic colorectal cancer treatment. Supportive Care in Cancer 2023; 31(8) doi: 10.1007/s00520-023-07973-3
|
| 7 |
Júlia Kanaan Recuero, Joana Roberta Fitz, Andrea Abe Pereira, Renan Rangel Bonamigo. EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects. Anais Brasileiros de Dermatologia 2023; 98(4): 429 doi: 10.1016/j.abd.2022.10.004
|
| 8 |
Mario E. Lacouture, Milan Anadkat, Aminah Jatoi, Tamer Garawin, Chet Bohac, Edith Mitchell. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clinical Colorectal Cancer 2018; 17(2): 85 doi: 10.1016/j.clcc.2017.12.004
|
| 9 |
Zimin Zhang, Mingyang Zhu, Weiwei Jiang. Risk Factors Analysis of Cutaneous Adverse Drug Reactions Caused by Targeted Therapy and Immunotherapy Drugs for Oncology and Establishment of a Prediction Model. Clinical and Translational Science 2025; 18(1) doi: 10.1111/cts.70118
|
| 10 |
George Kafatos, Sabada Dube, Peter Burdon, Gaston Demonty, Alain Flinois, Marjorie Leclerc, Kimberly Lowe, Maurille Feudjo-Tepie, Siegfried Segaert. Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients’ Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers. Clinical Colorectal Cancer 2020; 19(2): 100 doi: 10.1016/j.clcc.2020.01.001
|
| 11 |
Matthias F. Froelich, Sebastian Stintzing, Jörg Kumbrink, Thomas G.P. Grünewald, Ulrich Mansmann, Volker Heinemann, Thomas Kirchner, Andreas Jung. The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab. Oncotarget 2018; 9(54): 30279 doi: 10.18632/oncotarget.25689
|
| 12 |
J. Fernández-Mateos, R. Seijas-Tamayo, R. Mesía, M. Taberna, M. Pastor Borgoñón, E. Pérez-Ruiz, J.C. Adansa Klain, S. Vázquez Fernández, E. del Barco Morillo, A. Lozano, R. González Sarmiento, J.J. Cruz-Hernández. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population. Oral Oncology 2016; 63: 38 doi: 10.1016/j.oraloncology.2016.10.006
|
| 13 |
Ekaterina V. Orlova, Olga Yu. Olisova. The role of polymorphism of the epidermal growth factor gene in the formation of severe manifestations of skin toxicity caused by the use of EGFR inhibitors. Russian Journal of Skin and Venereal Diseases 2023; 26(5): 431 doi: 10.17816/dv108023
|